Spanish blood products firm Grifols (GRLS.MC) said on Monday it had agreed to sell some of its assets and make commercial agreements that could see its planned $4 billion takeover of U.S. rival Talecris (TLCR.O) approved by U.S. authorities. The group said it would sell two plasma centres as well as other assets and would make commercial agreements with Italian firm Kedrion. The Barcelona-based company said the agreements needed regulatory approval but were part of its process to rubber-stamp a protracted merger with Talecris (TLCR.O). Grifols shares were around 7.6 percent higher at 1030 GMT
Talecris Biotherapeutics Holdings Corp. is a biopharmaceutical company that produces and markets plasma-derived protein therapies. Shares of TLCR remained unchanged at $27.92. In the past year, the shares have traded as low as $15.70 and as high as $28.36. On average, 1156420 shares of TLCR exchange hands on a given day and today's volume is recorded at 100.
Talecris Biotherapeutics Holdings Corp. is a biopharmaceutical company that produces and markets plasma-derived protein therapies. Shares of TLCR remained unchanged at $27.92. In the past year, the shares have traded as low as $15.70 and as high as $28.36. On average, 1156420 shares of TLCR exchange hands on a given day and today's volume is recorded at 100.
Source
